Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 6 to Less Than 18 Years Old

NCT05905926 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT05905926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05905926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 6 to Less Than 18 Years Old
Lead sponsor
Ardelyx
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
February 17, 2023
Completion date
October 31, 2031
Enrollment
150 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with constipation (ibs-c)